These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 11830535)
1. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535 [TBL] [Abstract][Full Text] [Related]
2. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155 [TBL] [Abstract][Full Text] [Related]
3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Anderson LD; Mori S; Mann S; Savary CA; Mullen CA Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Anderson LD; Petropoulos D; Everse LA; Mullen CA Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624 [TBL] [Abstract][Full Text] [Related]
5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM; Waller EK Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [TBL] [Abstract][Full Text] [Related]
6. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
7. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
8. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells. Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530 [TBL] [Abstract][Full Text] [Related]
9. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Moyer JS; Maine G; Mulé JJ Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367 [TBL] [Abstract][Full Text] [Related]
10. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
11. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion. Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931 [TBL] [Abstract][Full Text] [Related]
12. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235 [TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844 [TBL] [Abstract][Full Text] [Related]
14. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Korngold R; Leighton C; Manser T Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387 [TBL] [Abstract][Full Text] [Related]
15. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564 [TBL] [Abstract][Full Text] [Related]
16. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Jones SC; Friedman TM; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075 [TBL] [Abstract][Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
18. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation. Bhattacharyya S; Cowan MJ Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats. Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650 [TBL] [Abstract][Full Text] [Related]
20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]